Vancouver, BC / TheNewswire / December 14, 2018 - SOLARVEST BIOENERGY INC. (TSX-V:SVS) ("Solarvest" or the "Company"), announces that it has received an extension from the TSX Venture Exchange ("TSX-V") with respect to the duration of its private placement announced on November 1, 2018. As a result, subject to regulatory approval, the closing date will now be on or about January 16, 2019.
Solarvest BioEnergy Inc. is an algae technology company whose algal-based production platform provides it with an extremely flexible system capable of being adapted to produce numerous products - from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein. In addition, the company's platform has successfully produced recombinant viral antigens (immune stimulating proteins,) Cecropins (antimicrobial pepetide/protein). The company has completed a feasibility study for the expression of CBD and THC.as a way to produce CBD and THC in sterile bioreactors.
For further information contact:
Tel: 416 420 0947 Email: email@example.com
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company's expectations and projections.